Table 2. Additional Characteristics of Patients Diagnosed With Cancer in California and Georgia and Reported to Surveillance, Epidemiology, and End Results (SEER) Registries From 2013 to 2019 by Germline Genetic Testing Statusa.
| Breast (female) | Breast (male) | Colorectal | Endometrial | Lung | Ovarian | Pancreatic | Prostate | Multiple cancer types | All other cancer types | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Tested, % | No. | Tested, % | No. | Tested, % | No. | Tested, % | No. | Tested, % | No. | Tested, % | No. | Tested, % | No. | Tested, % | No. | Tested, % | No. | Tested, % | |
| Overall | 203 575 | 26.0 | 1344 | 50.0 | 93 562 | 5.6 | 38 324 | 6.4 | 103 139 | 0.3 | 16 444 | 38.6 | 30 595 | 5.6 | 140 810 | 1.1 | 231 261 | 7.5 | 510 548 | 0.9 |
| Poverty assessed at the US Census tract level | ||||||||||||||||||||
| Low (<10%) | 106 118 | 27.9 | 710 | 54.1 | 42 010 | 6.5 | 18 226 | 7.0 | 43 766 | 0.4 | 8241 | 43.0 | 14 827 | 7.4 | 72 408 | 1.4 | 125 222 | 8.1 | 255 603 | 1.0 |
| Medium (10%-19%) | 62 000 | 24.4 | 400 | 47.5 | 30 956 | 5.3 | 12 559 | 6.1 | 34 546 | 0.3 | 5149 | 35.9 | 9458 | 4.3 | 42 555 | 0.8 | 68 738 | 6.9 | 158 704 | 0.8 |
| High (≥20%) | 35 457 | 22.9 | 234 | 41.9 | 20 596 | 4.4 | 7539 | 5.2 | 24 827 | 0.2 | 3054 | 31.2 | 6310 | 3.3 | 25 847 | 0.6 | 37 301 | 6.3 | 96 241 | 0.7 |
| Zip code classified by SEER | ||||||||||||||||||||
| Urban | 190 340 | 26.1 | 1245 | 50.1 | 85 984 | 5.7 | 35 673 | 6.4 | 92 393 | 0.3 | 15 351 | 38.6 | 28 264 | 5.7 | 129 858 | 1.1 | 213 129 | 7.6 | 471 730 | 0.9 |
| Rural | 13 235 | 24.2 | 99 | 48.5 | 7578 | 4.9 | 2651 | 5.2 | 10 746 | 0.2 | 1093 | 38.0 | 2331 | 4.4 | 10 952 | 0.9 | 18 132 | 6.3 | 38 818 | 0.7 |
| Cancer stageb | ||||||||||||||||||||
| 0 | 35 224 | 20.3 | 138 | 46.4 | 4640 | 2.5 | 142 | 2.1 | 289 | 0.7 | 38 | 28.9 | 223 | 1.3 | NA | NA | NA | NA | ||
| I | 82 431 | 25.7 | 399 | 54.1 | 19 152 | 4.6 | 26 416 | 6.0 | 18 694 | 0.5 | 3080 | 34.7 | 3503 | 6.0 | 29 557 | 0.5 | NA | NA | NA | NA |
| II | 50 216 | 30.6 | 433 | 54.7 | 19 325 | 6.3 | 1700 | 5.1 | 6953 | 0.2 | 1235 | 44.0 | 6045 | 6.2 | 62 491 | 0.6 | NA | NA | NA | NA |
| III | 17 030 | 32.2 | 180 | 49.4 | 22 690 | 7.4 | 4552 | 8.6 | 18 195 | 0.3 | 5970 | 45.1 | 2892 | 9.8 | 16 696 | 1.8 | NA | NA | NA | NA |
| IV | 9398 | 19.7 | 115 | 40.0 | 19 685 | 6.1 | 3255 | 9.0 | 52 395 | 0.3 | 5156 | 36.1 | 15 285 | 5.0 | 15 620 | 3.7 | NA | NA | NA | NA |
Abbreviation: NA, not applicable.
a
Includes genetic tests performed after and within 2 years of diagnosis from January 1, 2013, through March 31, 2021.
b
Stage was obtained from SEER-derived American Joint Committee on Cancer 7 stage group (North American Association of Central Cancer Registries [NAACCR] variable 3430) for cases diagnosed before 2018 and SEER-derived extent of disease 2018 stage group (NAACCR variable 818) for cases diagnosed during or after 2018. Stage was omitted for categories including more than 1 cancer type (eg, multiple cancer types and all other cancer types).